Prosecution Insights
Last updated: April 19, 2026
Application No. 18/615,334

METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF HYPERCYTOKINEMIA AND SEVERE INFLUENZA

Non-Final OA §112
Filed
Mar 25, 2024
Examiner
RAHMANI, NILOOFAR
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Poolbeg Pharma (Uk) Limited
OA Round
1 (Non-Final)
77%
Grant Probability
Favorable
1-2
OA Rounds
2y 1m
To Grant
74%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
871 granted / 1128 resolved
+17.2% vs TC avg
Minimal -3% lift
Without
With
+-2.9%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
12 currently pending
Career history
1140
Total Applications
across all art units

Statute-Specific Performance

§101
2.2%
-37.8% vs TC avg
§103
12.6%
-27.4% vs TC avg
§102
25.2%
-14.8% vs TC avg
§112
35.8%
-4.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1128 resolved cases

Office Action

§112
DETAILED ACTION Claims 89-105 are pending in the instant application. 2. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 89, 93-105 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim contains subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The specification lacks enablement of the term “p38MAP kinase inhibitor”, which are claimed in the method claims. While enabling for “p38MAP kinase inhibitor” example in claims 90-93, formula (I), formula (II), formula (III), it is not seen this is enables for other types of “p38MAP kinase inhibitor”. Therefore, the specification lacks enablement for the term “p38MAP kinase inhibitor” other than formula (I), formula (II), formula (III) in claims 90-93. 3. Claim Objections Claims 90-92 are objected to as being dependent upon a rejected base claim 89, but would be allowable if rewritten in independent form including all of the limitations of the base claims and any intervening claims. 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is 571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /NILOOFAR RAHMANI/ 12/05/2025
Read full office action

Prosecution Timeline

Mar 25, 2024
Application Filed
Mar 25, 2024
Response after Non-Final Action
Apr 18, 2024
Response after Non-Final Action
Dec 05, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12595249
ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS
2y 5m to grant Granted Apr 07, 2026
Patent 12582718
INTEGRIN TARGETING LIGANDS AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577242
PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS
2y 5m to grant Granted Mar 17, 2026
Patent 12577245
SULFONYL BENZAMIDE DERIVATIVES AS BCL-2 INHIBITORS
2y 5m to grant Granted Mar 17, 2026
Patent 12570655
CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
77%
Grant Probability
74%
With Interview (-2.9%)
2y 1m
Median Time to Grant
Low
PTA Risk
Based on 1128 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month